NASDAQ:CRME TSX:COM
VANCOUVER, Feb. 8, 2018 /CNW/ - Cardiome Pharma
Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty
pharmaceutical company focused on commercializing patent-protected
hospital drugs, today announced that Dr. Bill Hunter, President and CEO of Cardiome, will
participate in a fireside chat at the Leerink Partners 7th Annual
Global Healthcare Conference. The presentation will take place at
the Lotte New York Palace on Thursday,
February 15, 2018 at 1:30 p.m.
EST.
The webcast of Dr. Hunter's presentation can be accessed through
the following link: http://wsw.com/webcast/leerink30/crme/
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a revenue-generating, specialty
pharmaceutical company focused on providing innovative,
high-quality brands that meet the needs of acute care physicians
and patients. With a commercial presence and distribution
network covering over 60 countries worldwide, Cardiome develops,
acquires and commercializes brands for the in-hospital, acute care
market segment. The Company's portfolio of approved and
marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for
the treatment of acute bacterial skin and skin structure infections
(ABSSSI); Zevtera®/Mabelio® (ceftobiprole
medocaril sodium), a cephalosporin antibiotic for the treatment of
community- and hospital-acquired pneumonia (CAP, HAP), excluding
ventilator-associated pneumonia (VAP); Brinavess®
(vernakalant IV) for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm; Aggrastat® (tirofiban
hydrochloride) for the reduction of thrombotic cardiovascular
events in patients with acute coronary syndrome, and
Esmocard® and Esmocard Lyo® (esmolol
hydrochloride), a short-acting beta-blocker used to control rapid
heart rate in a number of cardiovascular indications.
Cardiome's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to
deliver Remodulin® (treprostinil) the world's leading
treatment for pulmonary arterial hypertension.
Cardiome is traded on the NASDAQ Capital Market (CRME) and the
Toronto Stock Exchange (COM). For more information, please visit
our web site at www.cardiome.com.
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities
Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation ("forward-looking
statements") that may not be based on historical fact, including
without limitation statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate",
"intend", "expect" and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. A discussion of the risks and uncertainties facing
Cardiome are discussed in our most recent annual and quarterly
reports and detailed from time to time in our other filings with
the Securities and Exchange Commission ("SEC") available at
www.sec.gov and the Canadian securities regulatory authorities at
www.sedar.com. All of the risks and certainties disclosed in
these filings are hereby incorporated by reference in their
entirety. While Cardiome makes these forward-looking statements in
good faith, given these risks, uncertainties and factors, you are
cautioned not to place undue reliance on any forward-looking
statements made in this press release. All forward-looking
statements made herein are based on our current expectations and we
undertake no obligation to revise or update such forward-looking
statements to reflect subsequent events or circumstances, except as
required by law.
Cardiome® and the Cardiome Logo are the proprietary
trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks
owned by Cardiome and its affiliates worldwide.
Xydalba® is a trademark of Durata Therapeutics Holding
C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Esmocard® and Esmocard Lyo® are trademarks
owned by Orpha-Devel Handels und Vertriebs GmbH, and used under
license.
Trevyent® is a trademark of SteadyMed and used under
license.
All other trademarks are the property of their respective
owners.
SOURCE Cardiome Pharma Corp.